Roche To Invest CHF240 Million In German Diagnostics Production
First Published Wednesday, 12th December 2012 06:22 am - © 2012 Dow Jones
ZURICH -- Roche Holding AG (ROG.VX) Wednesday said it will invest more than 240 million Swiss francs in its Penzberg biotechnology centre, located near Munich, Germany, to help meet rising demand for diagnostic products.
- The plans call for construction of a new production facility, to be known as Diagnostics Operations Complex II (DOCII).
- The facility is scheduled to be operational in December 2014 and will create 50 new jobs.
- This further investment in the Penzberg site is a response to sustained global demand for the reagents used in immunoassay testing in laboratories and hospitals.
- Immunoassays play a key role in the diagnosis and management of many diseases, including life-threatening conditions such as heart attack, heart failure, hepatitis and cancer
Subscribe to WSJ: http://online.wsj.com?mod=djnwires